John McArdle, MD
Pulmonary Disease · Hartford, CTNPI 1124001284
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by GSK at 48.9% of the total. Reporting peaked in 2019 at $290 and has fallen 94.2% since, to $17 in 2025. That places this record below the midpoint for pulmonary disease clinicians in CT, where the typical reported total is $1,017.
Across 75 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$581
- Actelion Pharmaceuticals US, Inc.$131
- Intuitive Surgical$119
- Insmed, Inc.$68
- Mylan Specialty L.p.$44
- ZOLL Respicardia, Inc.$38
- plus $206 from 10 others
Across 8 payments — averaging $11,103 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$89K
What the payments were for
- Food & beverage$1,17699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 43 | $581 |
| Actelion Pharmaceuticals US, Inc. | 11 | $131 |
| Intuitive Surgical | 1 | $119 |
| Insmed, Inc. | 4 | $68 |
| Mylan Specialty L.p. | 3 | $44 |
| ZOLL Respicardia, Inc. | 1 | $38 |
| Baxter Healthcare | 2 | $32 |
| Johnson & Johnson | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Cerus Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Pulmonx Corporation | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,187 in reported general payments places this provider in the 50th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 115 | $1,563,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 940 | $946,256 |
| UptraviSelexipag | 29 | $550,968 |
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 12 | $462,729 |
| WinrevairSotatercept-Csrk | 14 | $203,451 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 237 | $196,301 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $184,066 |
| OpsumitMacitentan | 12 | $176,490 |
| LetairisAmbrisentan | 11 | $140,952 |
| Breo ElliptaFluticasone/Vilanterol | 209 | $121,456 |
| Spiriva RespimatTiotropium Bromide | 134 | $113,303 |
| Ambrisentan | 26 | $107,642 |
| EsbrietPirfenidone | 11 | $106,155 |
| Dupixent PenDupilumab | 25 | $100,626 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $79,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $18 | $1,725,193292 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $581 | $1,297,7751,461 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $131 | $727,45841 claims |
| Insmed, Inc.Arikayce | $68 | $184,06612 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $12 | $155,468267 claims |
| Genentech USA, Inc.Esbriet | $17 | $106,15511 claims |
| Johnson & JohnsonXarelto | $27 | $38,89532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Hartford
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Jeffrey NascimentoHartford$213K
- Daniel GerardiHartford$156K
- James PopeHartford$125K
- Anil MaggeHartford$74K
- Francoise RouxHartford$39K
- Eric ShoreHartford$35K
- John RussomannoHartford$18K
- Meredith HolubHartford$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.